Ciltacabtagene autoleucel (Carvykti®). HTA ID: 22021

Assessment Status Awaiting response from Applicant
HTA ID 22021
Drug Ciltacabtagene autoleucel
Brand Carvykti®
Indication For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Assessment Process
Rapid review commissioned 11/04/2022
Rapid review completed 12/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cilta-cel (ciltacabtagene autoleucel) compared with the current standard-of-care.
Full pharmacoeconomic assessment commissioned by HSE 27/05/2022
Pre-submission consultation with Applicant 12/07/2022
Full submission received from Applicant 30/11/2022
Preliminary review sent to Applicant 30/05/2023